Calcitonin Gene Related Peptide (CGRP) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Calcitonin Gene Related Peptide (CGRP) – Pipeline Review, H2 2016’, provides in depth analysis on Calcitonin Gene Related Peptide (CGRP) targeted pipeline therapeutics.

The report provides comprehensive information on the Calcitonin Gene Related Peptide (CGRP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)

The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Alder Biopharmaceuticals Inc.

Boehringer Ingelheim GmbH

Eli Lilly and Company

Noxxon Pharma AG

Teva Pharmaceutical Industries Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Calcitonin Gene Related Peptide (CGRP) Overview 6

Therapeutics Development 7

Calcitonin Gene Related Peptide (CGRP) - Products under Development by Stage of Development 7

Calcitonin Gene Related Peptide (CGRP) - Products under Development by Therapy Area 8

Calcitonin Gene Related Peptide (CGRP) - Products under Development by Indication 9

Calcitonin Gene Related Peptide (CGRP) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Calcitonin Gene Related Peptide (CGRP) - Products under Development by Companies 12

Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development 20

Alder Biopharmaceuticals Inc. 20

Boehringer Ingelheim GmbH 21

Eli Lilly and Company 22

Noxxon Pharma AG 23

Teva Pharmaceutical Industries Ltd. 24

Calcitonin Gene Related Peptide (CGRP) - Drug Profiles 25

ALD-403 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

galcanezumab - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

NOXL-41 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

olcegepant - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

TEV-48125 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Calcitonin Gene Related Peptide (CGRP) - Dormant Projects 38

Calcitonin Gene Related Peptide (CGRP) - Discontinued Products 40

Calcitonin Gene Related Peptide (CGRP) - Featured News & Press Releases 41

Sep 08, 2016: Alder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention 41

Sep 06, 2016: Alder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer 41

Jul 25, 2016: Alder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine 42

Jun 09, 2016: Alder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society 43

Jun 08, 2016: New drug to prevent migraine may start working in days 44

Jun 02, 2016: Alder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention 45

May 25, 2016: Alder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention 46

Apr 12, 2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting 47

Mar 28, 2016: Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in Patients with Chronic Migraine 47

Feb 09, 2016: Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization 49

Oct 13, 2015: Alder BioPharmaceuticals Initiates Pivotal Clinical Trial of ALD403 for Preventative Treatment of Frequent Episodic Migraine 50

Sep 30, 2015: Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Articles 51

Jun 18, 2015: Teva to Present New Findings at the American Headache Society Meeting - Analysis of Migraine Phase IIb Studies Provides Novel Insights into TEV-48125 Efficacy and Safety in Both Episodic & Chronic Migraine 52

Jun 17, 2015: Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study 54

May 15, 2015: Alder Presents Positive Clinical Data for ALD403 at the 17th Congress of the International Headache Society 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Alder Biopharmaceuticals Inc., H2 2016 20

Pipeline by Boehringer Ingelheim GmbH, H2 2016 21

Pipeline by Eli Lilly and Company, H2 2016 22

Pipeline by Noxxon Pharma AG, H2 2016 23

Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 24

Dormant Projects, H2 2016 38

Dormant Projects (Contd..1), H2 2016 39

Discontinued Products, H2 2016 40

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Indication, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 17

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared